Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G, Pronzato P, Bruzzi P. Del Mastro L, et al. Among authors: bruzzi p. Cancer Treat Rev. 2014 Jun;40(5):675-83. doi: 10.1016/j.ctrv.2013.12.001. Epub 2013 Dec 8. Cancer Treat Rev. 2014. PMID: 24360817 Review.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups. Lambertini M, et al. Among authors: bruzzi p. Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10. Eur J Cancer. 2017. PMID: 27951450 Clinical Trial.
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L. Lambertini M, et al. Among authors: bruzzi p. Ann Oncol. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347105 Free article. Review.
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, Blondeaux E, Sertoli MR, Pronzato P, Del Mastro L. Poggio F, et al. Among authors: bruzzi p. Breast. 2017 Jun;33:104-108. doi: 10.1016/j.breast.2017.03.011. Epub 2017 Mar 27. Breast. 2017. PMID: 28360014 Review.
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.
Bighin C, Dozin B, Poggio F, Ceppi M, Bruzzi P, D'Alonzo A, Levaggi A, Giraudi S, Lambertini M, Miglietta L, Vaglica M, Fontana V, Iacono G, Pronzato P, Del Mastro L. Bighin C, et al. Among authors: bruzzi p. Oncotarget. 2017 Jul 4;8(27):44800-44810. doi: 10.18632/oncotarget.14735. Oncotarget. 2017. PMID: 28108743 Free PMC article.
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.
Lambertini M, Bruzzi P, Poggio F, Pastorino S, Gardin G, Clavarezza M, Bighin C, Pronzato P, Del Mastro L. Lambertini M, et al. Among authors: bruzzi p. Support Care Cancer. 2016 Mar;24(3):1285-94. doi: 10.1007/s00520-015-2907-2. Epub 2015 Aug 27. Support Care Cancer. 2016. PMID: 26306520 Clinical Trial.
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Del Mastro L, Levaggi A, Michelotti A, Cavazzini G, Adami F, Scotto T, Piras M, Danese S, Garrone O, Durando A, Accortanzo V, Bighin C, Miglietta L, Pastorino S, Pronzato P, Castiglione F, Landucci E, Conte P, Bruzzi P. Del Mastro L, et al. Among authors: bruzzi p. Breast Cancer Res Treat. 2016 Jan;155(1):117-26. doi: 10.1007/s10549-015-3655-1. Epub 2015 Dec 10. Breast Cancer Res Treat. 2016. PMID: 26661403 Clinical Trial.
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Blondeaux E, Musio D, Bruzzi P, Lambertini M, Gazzola V, Poggio F, Vecchio S, Levaggi A, D'Alonzo A, Perfumo MC, Bighin C, Giraudi S, Palombo D, Del Mastro L. Blondeaux E, et al. Among authors: bruzzi p. Breast Cancer Res Treat. 2016 Nov;160(2):261-267. doi: 10.1007/s10549-016-3985-7. Epub 2016 Sep 23. Breast Cancer Res Treat. 2016. PMID: 27663435
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group.
Del Mastro L, Dozin B, Aitini E, Catzeddu T, Baldini E, Contu A, Durando A, Danese S, Cavazzini G, Canavese G, Bruzzi P, Pronzato P, Venturini M; GONO-MIG Group. Del Mastro L, et al. Among authors: bruzzi p. Ann Oncol. 2008 Feb;19(2):299-307. doi: 10.1093/annonc/mdm475. Epub 2007 Oct 17. Ann Oncol. 2008. PMID: 17947224 Free article.
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
Del Mastro L, Bruzzi P, Nicolò G, Cavazzini G, Contu A, D'Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini M. Del Mastro L, et al. Among authors: bruzzi p. Br J Cancer. 2005 Jul 11;93(1):7-14. doi: 10.1038/sj.bjc.6602660. Br J Cancer. 2005. PMID: 15970926 Free PMC article. Clinical Trial.
395 results